Showing results (501-510 of 532) with videos related to
Sort By:
Pageof 54
Blood|March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1qRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.Blood|May 19, 2017
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaMichelle M McDonald, Michaela R Reagan, Scott E Youlten, et al.Current Cancer Drug Targets|January 21, 2011
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsB C Potts, M X Albitar, K C Anderson, et al.Haematologica|May 28, 2026
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myelomaOmar Nadeem, Robert A Redd, Peter M Barth, et al.The Lancet. Haematology|March 1, 2023
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort studyAnnie Cowan, Federico Ferrari, Samuel S Freeman, et al.Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.Global Spine Journal|January 15, 2020
Minimizing Blood Loss in Spine SurgeryChristopher Mikhail, Zach Pennington, Paul M Arnold, et al.Blood Advances|March 21, 2024
Genomic profiling of mycosis fungoides identifies patients at high risk of disease progressionLéa Fléchon, Inès Arib, Ankit K Dutta, et al.The Lancet. Haematology|March 28, 2022
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort studyHabib El-Khoury, David J Lee, Jean-Baptiste Alberge, et al.Blood Cancer Discovery|June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple MyelomaFaith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.Pageof 54